Annual Reports in Medicinal Chemistry
Volume 44
Herausgegeben:Macor, John E.
Annual Reports in Medicinal Chemistry
Volume 44
Herausgegeben:Macor, John E.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
Andere Kunden interessierten sich auch für
![Annual Reports in Medicinal Chemistry]( "Annual Reports in Medicinal Chemistry")
Annual Reports in Medicinal Chemistry101,99 €![Annual Reports in Medicinal Chemistry]( "Annual Reports in Medicinal Chemistry")
Annual Reports in Medicinal Chemistry96,99 €![Annual Reports in Medicinal Chemistry]( "Annual Reports in Medicinal Chemistry")
Annual Reports in Medicinal Chemistry94,99 €![Annual Reports on NMR Spectroscopy]( "Annual Reports on NMR Spectroscopy")
Annual Reports on NMR Spectroscopy151,99 €![Annual Reports on NMR Spectroscopy]( "Annual Reports on NMR Spectroscopy")
Annual Reports on NMR Spectroscopy134,99 €![Annual Reports on NMR Spectroscopy]( "Annual Reports on NMR Spectroscopy")
Graham A. Webb (ed.)Annual Reports on NMR Spectroscopy161,99 €![Annual Reports on NMR Spectroscopy]( "Annual Reports on NMR Spectroscopy")
Annual Reports on NMR Spectroscopy134,99 €-
-
-
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
Produktdetails
- Produktdetails
- Annual Reports in Medicinal Chemistry Volume 44
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: C2009-0-19795-7
- Seitenzahl: 736
- Erscheinungstermin: 1. Oktober 2009
- Englisch
- Abmessung: 226mm x 152mm x 33mm
- Gewicht: 1200g
- ISBN-13: 9780123747662
- ISBN-10: 012374766X
- Artikelnr.: 27347631
- Annual Reports in Medicinal Chemistry Volume 44
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: C2009-0-19795-7
- Seitenzahl: 736
- Erscheinungstermin: 1. Oktober 2009
- Englisch
- Abmessung: 226mm x 152mm x 33mm
- Gewicht: 1200g
- ISBN-13: 9780123747662
- ISBN-10: 012374766X
- Artikelnr.: 27347631
1 Recent advances in the discovery of GSK-3 inhibitors and a
perspective on their utility for the treatment of Alzheimer's
disease
Robert G. Gentles, Shuanghua Hu,
and. Gene Dubowchik
2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash
Annendi, Jailall Remnauth, and
Suman Rakhit
3 Small Molecule Protein-Protein Interaction Inhibitors as
Therapeutic Agents for Neurodegenerative Diseases: Current
Progress and Future Hurdles
Simon Haydar and Warren Hirst
4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial
Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and
Brian T. O'Neill
5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly
Efficacious Direct Oral Renin Inhibitor as a New Therapy for
Hypertension
Juergen Maibaum and David Feldman
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones
8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers
9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer
10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey
11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones
12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski
13 Recent Advances in Adenosine Receptor (AR) Ligands in
Pulmonary Diseases
Jeff Zablocki and Rao Kalla
14 Recent Progress in the Development of Small Molecule Inhibitors
of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman
15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass
Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.
16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin
17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-
3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako
and Neel K. Anand Exelixis
18 Anti-infective Activity of Artemisinin and its Semi-synthetic
Derivatives John G. D'Angelo
19 Recent Advances in the Inhibition of Bacterial Type II
Topoisomerases
Greg Bisacchi & Jacques Dumas
20 Progress Towards the Discovery and Development of Specifically
Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F.
Kadow and Paul M. Scol
21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor
Coactivator Interactions
Terry Moore, John Katzenellenbogen
22 Safety Testing of Drug Metabolites Tom Thompson
23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz
24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy
25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore
26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray
27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car
28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt
perspective on their utility for the treatment of Alzheimer's
disease
Robert G. Gentles, Shuanghua Hu,
and. Gene Dubowchik
2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash
Annendi, Jailall Remnauth, and
Suman Rakhit
3 Small Molecule Protein-Protein Interaction Inhibitors as
Therapeutic Agents for Neurodegenerative Diseases: Current
Progress and Future Hurdles
Simon Haydar and Warren Hirst
4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial
Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and
Brian T. O'Neill
5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly
Efficacious Direct Oral Renin Inhibitor as a New Therapy for
Hypertension
Juergen Maibaum and David Feldman
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones
8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers
9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer
10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey
11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones
12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski
13 Recent Advances in Adenosine Receptor (AR) Ligands in
Pulmonary Diseases
Jeff Zablocki and Rao Kalla
14 Recent Progress in the Development of Small Molecule Inhibitors
of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman
15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass
Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.
16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin
17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-
3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako
and Neel K. Anand Exelixis
18 Anti-infective Activity of Artemisinin and its Semi-synthetic
Derivatives John G. D'Angelo
19 Recent Advances in the Inhibition of Bacterial Type II
Topoisomerases
Greg Bisacchi & Jacques Dumas
20 Progress Towards the Discovery and Development of Specifically
Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F.
Kadow and Paul M. Scol
21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor
Coactivator Interactions
Terry Moore, John Katzenellenbogen
22 Safety Testing of Drug Metabolites Tom Thompson
23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz
24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy
25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore
26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray
27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car
28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt
1 Recent advances in the discovery of GSK-3 inhibitors and a
perspective on their utility for the treatment of Alzheimer's
disease
Robert G. Gentles, Shuanghua Hu,
and. Gene Dubowchik
2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash
Annendi, Jailall Remnauth, and
Suman Rakhit
3 Small Molecule Protein-Protein Interaction Inhibitors as
Therapeutic Agents for Neurodegenerative Diseases: Current
Progress and Future Hurdles
Simon Haydar and Warren Hirst
4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial
Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and
Brian T. O'Neill
5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly
Efficacious Direct Oral Renin Inhibitor as a New Therapy for
Hypertension
Juergen Maibaum and David Feldman
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones
8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers
9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer
10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey
11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones
12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski
13 Recent Advances in Adenosine Receptor (AR) Ligands in
Pulmonary Diseases
Jeff Zablocki and Rao Kalla
14 Recent Progress in the Development of Small Molecule Inhibitors
of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman
15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass
Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.
16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin
17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-
3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako
and Neel K. Anand Exelixis
18 Anti-infective Activity of Artemisinin and its Semi-synthetic
Derivatives John G. D'Angelo
19 Recent Advances in the Inhibition of Bacterial Type II
Topoisomerases
Greg Bisacchi & Jacques Dumas
20 Progress Towards the Discovery and Development of Specifically
Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F.
Kadow and Paul M. Scol
21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor
Coactivator Interactions
Terry Moore, John Katzenellenbogen
22 Safety Testing of Drug Metabolites Tom Thompson
23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz
24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy
25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore
26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray
27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car
28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt
perspective on their utility for the treatment of Alzheimer's
disease
Robert G. Gentles, Shuanghua Hu,
and. Gene Dubowchik
2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash
Annendi, Jailall Remnauth, and
Suman Rakhit
3 Small Molecule Protein-Protein Interaction Inhibitors as
Therapeutic Agents for Neurodegenerative Diseases: Current
Progress and Future Hurdles
Simon Haydar and Warren Hirst
4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial
Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and
Brian T. O'Neill
5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly
Efficacious Direct Oral Renin Inhibitor as a New Therapy for
Hypertension
Juergen Maibaum and David Feldman
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones
8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers
9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer
10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey
11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones
12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski
13 Recent Advances in Adenosine Receptor (AR) Ligands in
Pulmonary Diseases
Jeff Zablocki and Rao Kalla
14 Recent Progress in the Development of Small Molecule Inhibitors
of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman
15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass
Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.
16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin
17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-
3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako
and Neel K. Anand Exelixis
18 Anti-infective Activity of Artemisinin and its Semi-synthetic
Derivatives John G. D'Angelo
19 Recent Advances in the Inhibition of Bacterial Type II
Topoisomerases
Greg Bisacchi & Jacques Dumas
20 Progress Towards the Discovery and Development of Specifically
Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F.
Kadow and Paul M. Scol
21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor
Coactivator Interactions
Terry Moore, John Katzenellenbogen
22 Safety Testing of Drug Metabolites Tom Thompson
23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz
24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy
25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore
26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray
27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car
28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt